114 related articles for article (PubMed ID: 9238339)
1. Superoxide dismutase activity in early and advanced Parkinson's disease.
Bostantjopoulou S; Kyriazis G; Katsarou Z; Kiosseoglou G; Kazis A; Mentenopoulos G
Funct Neurol; 1997; 12(2):63-8. PubMed ID: 9238339
[TBL] [Abstract][Full Text] [Related]
2. Selegiline and lymphocyte superoxide dismutase activities in Parkinson's disease.
Kushleika J; Checkoway H; Woods JS; Moon JD; Smith-Weller T; Franklin GM; Swanson PD
Ann Neurol; 1996 Mar; 39(3):378-81. PubMed ID: 8602757
[TBL] [Abstract][Full Text] [Related]
3. Peripheral blood markers of oxidative stress in Parkinson's disease.
Younes-Mhenni S; Frih-Ayed M; Kerkeni A; Bost M; Chazot G
Eur Neurol; 2007; 58(2):78-83. PubMed ID: 17565220
[TBL] [Abstract][Full Text] [Related]
4. Erythrocyte superoxide dismutase activity differs in clinical subgroups of Parkinson's disease patients.
Akbostanci MC; Kocatürk PA; Tan FU; Kavas GO
Acta Neurol Belg; 2001 Sep; 101(3):180-3. PubMed ID: 11817268
[TBL] [Abstract][Full Text] [Related]
5. Neutrophil function, nitric oxide, and blood oxidative stress in Parkinson's disease.
Gatto EM; Carreras MC; Pargament GA; Riobo NA; Reides C; Repetto M; Fernandez Pardal MM; Llesuy S; Poderoso JJ
Mov Disord; 1996 May; 11(3):261-7. PubMed ID: 8723142
[TBL] [Abstract][Full Text] [Related]
6. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
[TBL] [Abstract][Full Text] [Related]
7. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
Im JH; Ha JH; Cho IS; Lee MC
J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
[TBL] [Abstract][Full Text] [Related]
8. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.
Katzenschlager R; Head J; Schrag A; Ben-Shlomo Y; Evans A; Lees AJ;
Neurology; 2008 Aug; 71(7):474-80. PubMed ID: 18579806
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
10. [Daily defined doses of parkinsonian drugs in Alcoi].
Manzanares R; Matías-Guiu J; Provencio R; Falip R; López-Arlandis J; Martín R; Ruiz C
Rev Neurol; 1996 Apr; 24(128):440-2. PubMed ID: 8721923
[TBL] [Abstract][Full Text] [Related]
11. Slowing of oscillatory brain activity is a stable characteristic of Parkinson's disease without dementia.
Stoffers D; Bosboom JL; Deijen JB; Wolters EC; Berendse HW; Stam CJ
Brain; 2007 Jul; 130(Pt 7):1847-60. PubMed ID: 17412733
[TBL] [Abstract][Full Text] [Related]
12. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
[TBL] [Abstract][Full Text] [Related]
13. Oxidative stress in peripheral blood mononuclear cells from patients with Parkinson's disease: negative correlation with levodopa dosage.
Prigione A; Begni B; Galbussera A; Beretta S; Brighina L; Garofalo R; Andreoni S; Piolti R; Ferrarese C
Neurobiol Dis; 2006 Jul; 23(1):36-43. PubMed ID: 16563783
[TBL] [Abstract][Full Text] [Related]
14. Endothelial function markers in parkinsonian patients with hyperhomocysteinemia.
Bostantjopoulou S; Katsarou Z; Frangia T; Hatzizisi O; Papazisis K; Kyriazis G; Kiosseoglou G; Kazis A
J Clin Neurosci; 2005 Aug; 12(6):669-72. PubMed ID: 16040247
[TBL] [Abstract][Full Text] [Related]
15. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
Jost WH; Klasser M; Reichmann H
Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
[TBL] [Abstract][Full Text] [Related]
16. Levodopa therapy reduces DNA damage in peripheral blood cells of patients with Parkinson's disease.
Cornetta T; Palma S; Aprile I; Padua L; Tonali P; Testa A; Cozzi R
Cell Biol Toxicol; 2009 Aug; 25(4):321-30. PubMed ID: 18523852
[TBL] [Abstract][Full Text] [Related]
17. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group.
Korczyn AD; Brooks DJ; Brunt ER; Poewe WH; Rascol O; Stocchi F
Mov Disord; 1998 Jan; 13(1):46-51. PubMed ID: 9452325
[TBL] [Abstract][Full Text] [Related]
18. No evidence for systemic oxidant stress in Parkinson's or Alzheimer's disease.
Ahlskog JE; Uitti RJ; Low PA; Tyce GM; Nickander KK; Petersen RC; Kokmen E
Mov Disord; 1995 Sep; 10(5):566-73. PubMed ID: 8552107
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson's disease: relationship to clinical data.
Ihara Y; Chuda M; Kuroda S; Hayabara T
J Neurol Sci; 1999 Nov; 170(2):90-5. PubMed ID: 10561523
[TBL] [Abstract][Full Text] [Related]
20. The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson's disease patients.
Stryjer R; Klein C; Treves TA; Rabey JM
Acta Neurol Scand; 2005 Feb; 111(2):89-94. PubMed ID: 15644067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
